Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 1521

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 8
Chunk 1521
---
 financial systems and cannot ensure there are no vulnerabilities in these systems.

Management’s
Report on Internal Control over Financial Reporting 

This
Report does not include a report of management’s assessment regarding internal control over financial reporting or an attestation
report of the Company’s registered public accounting firm due to a transition period established by rules of the SEC for
newly public companies. Additionally, our auditors will not be required to formally opine on the effectiveness of our internal
control over financial reporting pursuant to Section 404 until we are no longer an “emerging growth company” as defined
in the JOBS Act.

81 

Changes
in Internal Control over Financial Reporting 

There
were no changes in the Company’s internal control over financial reporting during the year ended December 31, 2024,
that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial
reporting.

Item
9B. Other Information

During
the three months ended December 31, 2024, none of our directors and officers adopted or terminated a “Rule 10b5-1 trading
arrangement” or “non-Rule 10b5-1 trading arrangement”, as each term is defined in Item 408(a) of Regulation
S-K.

Item
9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections

Not
applicable.

PART
III

Item
10. Directors, Executive Officers and Corporate Governance 

The
following table provides information regarding our current executive officers and directors:

    Name
    Age
    Position

    Executive
    Officers

    Francis
    Knuettel II
    58
    Chief
    Executive Officer and President, Chief Financial Officer, Treasurer and Secretary

    Eric
    Lang
    63
    Chief
    Medical Officer

    Directors

    Todd
    Davis
    64
    Director
    (Chairman of the Board)

    Ezra
    Friedberg
    55
    Director

    Richard
    Malamut
    65
    Director

    Chia-Lin
    Simmons
    51
    Director

    Francis
    Knuettel II 
    58
    Director

Biographic
Information 

Francis
Knuettel II has served as our Chief Executive Officer since July 2023, as our Chief Financial Officer, Treasurer and Secretary
since June 2022, as our Chief Executive Officer since March 2024,